10. Charcot-Marie-Tooth disease Clinical trials / Disease details

Clinical trials : 41 / Drugs : 46 - (DrugBank : 9) / Drug target genes : 11 - Drug target pathways : 15

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03943290 (ClinicalTrials.gov)	May 10, 2019	17/4/2019	Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)	An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients With Charcot-Marie Tooth (CMT) Disease Types 1 and X Previously Enrolled in Study A083-03	Facioscapulohumeral Muscular Dystrophy;Charcot-Marie-Tooth Disease	Drug: ACE-083	Acceleron Pharma, Inc.	NULL	Terminated	18 Years	N/A	All	62	Phase 2	United States;Canada;Spain
2	NCT03124459 (ClinicalTrials.gov)	July 31, 2017	12/4/2017	Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X	Charcot-Marie-Tooth Disease	Drug: ACE-083;Drug: Placebo	Acceleron Pharma, Inc.	NULL	Terminated	18 Years	N/A	All	62	Phase 2	United States